<?xml version="1.0" encoding="UTF-8"?>
<!-- This sitemap was dynamically generated on September 7, 2026 at 1:39 pm by All in One SEO v5.0.1.1 - the original SEO plugin for WordPress. -->

<?xml-stylesheet type="text/xsl" href="https://helixgatebiotechreview.com/default-sitemap.xsl"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>Helixgate</title>
		<link><![CDATA[https://helixgatebiotechreview.com]]></link>
		<description><![CDATA[Helixgate]]></description>
		<lastBuildDate><![CDATA[Mon, 07 Sep 2026 03:41:45 +0000]]></lastBuildDate>
		<docs>https://validator.w3.org/feed/docs/rss2.html</docs>
		<atom:link href="https://helixgatebiotechreview.com/sitemap.rss" rel="self" type="application/rss+xml" />
		<ttl><![CDATA[60]]></ttl>

		<item>
			<guid><![CDATA[https://bioengineer.org/gut-microbial-metabolites-shape-fusobacterium-growth-and-colorectal-cancer-behavior/]]></guid>
			<link><![CDATA[https://bioengineer.org/gut-microbial-metabolites-shape-fusobacterium-growth-and-colorectal-cancer-behavior/]]></link>
			<title>Gut microbial metabolites shape Fusobacterium growth and colorectal cancer behavior</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 03:41:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/video-based-leg-agility-scoring-in-parkinsons-disease-links-to-arm-motor-impairments/]]></guid>
			<link><![CDATA[https://bioengineer.org/video-based-leg-agility-scoring-in-parkinsons-disease-links-to-arm-motor-impairments/]]></link>
			<title>Video-based leg agility scoring in Parkinson’s disease links to arm motor impairments</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 23:50:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/turning-sorghum-stalk-lignocellulose-into-valuable-xylooligosaccharides-efficiently/]]></guid>
			<link><![CDATA[https://bioengineer.org/turning-sorghum-stalk-lignocellulose-into-valuable-xylooligosaccharides-efficiently/]]></link>
			<title>Turning sorghum stalk lignocellulose into valuable xylooligosaccharides efficiently</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 03:41:44 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/gerontology-group-backs-updated-immunization-guidance/]]></guid>
			<link><![CDATA[https://bioengineer.org/gerontology-group-backs-updated-immunization-guidance/]]></link>
			<title>Gerontology group backs updated immunization guidance</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 02:17:50 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/daraxonrasib-shows-early-antitumor-activity-in-ras-mutant-lung-cancer/]]></guid>
			<link><![CDATA[https://bioengineer.org/daraxonrasib-shows-early-antitumor-activity-in-ras-mutant-lung-cancer/]]></link>
			<title>Daraxonrasib shows early antitumor activity in RAS-mutant lung cancer</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 02:17:48 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/cocoa-shell-biochar-with-zif-8-removes-loratadine-from-water/]]></guid>
			<link><![CDATA[https://bioengineer.org/cocoa-shell-biochar-with-zif-8-removes-loratadine-from-water/]]></link>
			<title>Cocoa-shell biochar with ZIF-8 removes loratadine from water</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 02:17:41 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/newdrugs/fda-approves-zanvastro-zilganersen-alexander-6876.html]]></guid>
			<link><![CDATA[https://www.drugs.com/newdrugs/fda-approves-zanvastro-zilganersen-alexander-6876.html]]></link>
			<title>FDA Approves Zanvastro (zilganersen) for the Treatment of Alexander Disease</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 01:16:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/clinical_trials/novartis-announces-lp-horizon-phase-iii-topline-results-pelacarsen-patients-elevated-lp-established-22578.html]]></guid>
			<link><![CDATA[https://www.drugs.com/clinical_trials/novartis-announces-lp-horizon-phase-iii-topline-results-pelacarsen-patients-elevated-lp-established-22578.html]]></link>
			<title>Novartis Announces Lp(a)HORIZON Phase III Topline Results for Pelacarsen in Patients with Elevated Lp(a) and Established Cardiovascular Disease (CVD)</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 23:50:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/clinical_trials/stoke-therapeutics-biogen-present-long-term-clinical-data-support-modifying-potential-zorevunersen-22580.html]]></guid>
			<link><![CDATA[https://www.drugs.com/clinical_trials/stoke-therapeutics-biogen-present-long-term-clinical-data-support-modifying-potential-zorevunersen-22580.html]]></link>
			<title>Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 23:50:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/metabolomics-reveals-how-tubuloside-a-inhibits-streptococcus-suis-biofilms/]]></guid>
			<link><![CDATA[https://bioengineer.org/metabolomics-reveals-how-tubuloside-a-inhibits-streptococcus-suis-biofilms/]]></link>
			<title>Metabolomics reveals how tubuloside A inhibits Streptococcus suis biofilms</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 22:41:59 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/garlic-compound-blocks-key-signal-triggering-gastric-cancer-cell-death/]]></guid>
			<link><![CDATA[https://bioengineer.org/garlic-compound-blocks-key-signal-triggering-gastric-cancer-cell-death/]]></link>
			<title>Garlic compound blocks key signal, triggering gastric cancer cell death</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 22:41:57 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/new-machine-learning-model-predicts-ivig-resistance-in-kawasaki-disease/]]></guid>
			<link><![CDATA[https://bioengineer.org/new-machine-learning-model-predicts-ivig-resistance-in-kawasaki-disease/]]></link>
			<title>New machine learning model predicts IVIG resistance in Kawasaki disease</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 22:41:56 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/novel-kynureninase-inhibitor-ks79356-slows-triple-negative-breast-cancer-progression/]]></guid>
			<link><![CDATA[https://bioengineer.org/novel-kynureninase-inhibitor-ks79356-slows-triple-negative-breast-cancer-progression/]]></link>
			<title>Novel kynureninase inhibitor KS79356 slows triple-negative breast cancer progression</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 22:41:55 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/emotional-changes-in-chronically-ill-patients-after-a-complementary-therapy-support-program/]]></guid>
			<link><![CDATA[https://bioengineer.org/emotional-changes-in-chronically-ill-patients-after-a-complementary-therapy-support-program/]]></link>
			<title>Emotional Changes in Chronically Ill Patients After a Complementary Therapy Support Program</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 21:16:52 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/machine-learning-and-free-energy-methods-discover-new-tuberculosis-kasa-inhibitors/]]></guid>
			<link><![CDATA[https://bioengineer.org/machine-learning-and-free-energy-methods-discover-new-tuberculosis-kasa-inhibitors/]]></link>
			<title>Machine learning and free energy methods discover new tuberculosis KasA inhibitors</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 19:57:40 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/multiomics-reveals-synpo2-vnn1-target-and-microbiota-vaccine-for-atherosclerosis/]]></guid>
			<link><![CDATA[https://bioengineer.org/multiomics-reveals-synpo2-vnn1-target-and-microbiota-vaccine-for-atherosclerosis/]]></link>
			<title>Multiomics reveals SYNPO2/VNN1 target and microbiota vaccine for atherosclerosis</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 18:42:52 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/staff-perspectives-shape-cross-sector-care-for-dual-diagnosis-patients/]]></guid>
			<link><![CDATA[https://bioengineer.org/staff-perspectives-shape-cross-sector-care-for-dual-diagnosis-patients/]]></link>
			<title>Staff perspectives shape cross-sector care for dual diagnosis patients</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 16:02:53 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/treating-osteoporosis-in-older-men-review-of-drug-and-lifestyle-trials/]]></guid>
			<link><![CDATA[https://bioengineer.org/treating-osteoporosis-in-older-men-review-of-drug-and-lifestyle-trials/]]></link>
			<title>Treating osteoporosis in older men: review of drug and lifestyle trials</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 16:02:50 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/engineered-gitr-antibody-boosts-cd4-t-cell-dendritic-cell-teamwork-against-tumors/]]></guid>
			<link><![CDATA[https://bioengineer.org/engineered-gitr-antibody-boosts-cd4-t-cell-dendritic-cell-teamwork-against-tumors/]]></link>
			<title>Engineered GITR antibody boosts CD4 T cell-dendritic cell teamwork against tumors</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 14:50:19 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/mcc-protein-links-wnt-signaling-to-blood-vessel-polarity-and-remodeling/]]></guid>
			<link><![CDATA[https://bioengineer.org/mcc-protein-links-wnt-signaling-to-blood-vessel-polarity-and-remodeling/]]></link>
			<title>MCC protein links Wnt signaling to blood vessel polarity and remodeling</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 14:50:14 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/enhanced-info-algorithm-enables-multi-threshold-segmentation-of-colorectal-cancer-histopathology-images/]]></guid>
			<link><![CDATA[https://bioengineer.org/enhanced-info-algorithm-enables-multi-threshold-segmentation-of-colorectal-cancer-histopathology-images/]]></link>
			<title>Enhanced INFO algorithm enables multi-threshold segmentation of colorectal cancer histopathology images</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 13:29:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/15-pentanediamine-from-crkp-colonized-patients-weakens-cd19-car-t-cells-in-vitro/]]></guid>
			<link><![CDATA[https://bioengineer.org/15-pentanediamine-from-crkp-colonized-patients-weakens-cd19-car-t-cells-in-vitro/]]></link>
			<title>1,5-Pentanediamine from CRKP-colonized patients weakens CD19 CAR-T cells in vitro</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 12:18:16 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/french-expert-consensus-on-cladribine-tablets-for-relapsing-ms-beyond-year-4/]]></guid>
			<link><![CDATA[https://bioengineer.org/french-expert-consensus-on-cladribine-tablets-for-relapsing-ms-beyond-year-4/]]></link>
			<title>French expert consensus on cladribine tablets for relapsing MS beyond year 4</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 12:18:15 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/machine-learning-predicts-cdk4-6-inhibitor-outcomes-in-metastatic-breast-cancer/]]></guid>
			<link><![CDATA[https://bioengineer.org/machine-learning-predicts-cdk4-6-inhibitor-outcomes-in-metastatic-breast-cancer/]]></link>
			<title>Machine learning predicts CDK4/6 inhibitor outcomes in metastatic breast cancer</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 12:18:14 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/whole-genome-sequencing-reveals-genetic-predictors-of-rifabutin-susceptibility-in-multidrug-resistant-tuberculosis/]]></guid>
			<link><![CDATA[https://bioengineer.org/whole-genome-sequencing-reveals-genetic-predictors-of-rifabutin-susceptibility-in-multidrug-resistant-tuberculosis/]]></link>
			<title>Whole-genome sequencing reveals genetic predictors of rifabutin susceptibility in multidrug-resistant tuberculosis</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 12:16:18 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/summit-akesos-ivonescimab-bests-mercks-keytruda-in-china-trial-again]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/summit-akesos-ivonescimab-bests-mercks-keytruda-in-china-trial-again]]></link>
			<title>Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 11:31:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/ultragenyxs-high-risk-angelman-bet-fails-cratering-stock-and-forcing-strategic-review]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/ultragenyxs-high-risk-angelman-bet-fails-cratering-stock-and-forcing-strategic-review]]></link>
			<title>Ultragenyx’s &#8216;high-risk&#8217; Angelman bet fails, cratering stock and forcing strategic review</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 11:31:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/fda/replimunes-melanoma-drug-would-have-been-rejected-again-if-not-for-senior-cber-official]]></guid>
			<link><![CDATA[https://www.biospace.com/fda/replimunes-melanoma-drug-would-have-been-rejected-again-if-not-for-senior-cber-official]]></link>
			<title>Replimune’s melanoma drug would have been rejected again if not for senior CBER official</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 11:31:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/biospace-layoff-tracker]]></guid>
			<link><![CDATA[https://www.biospace.com/biospace-layoff-tracker]]></link>
			<title>TScan axes 75% of workforce, prioritizes solid tumor program</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 11:31:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/business/biotech-is-back-with-h1-progress-smoothing-glide-path-through-end-of-year-truist]]></guid>
			<link><![CDATA[https://www.biospace.com/business/biotech-is-back-with-h1-progress-smoothing-glide-path-through-end-of-year-truist]]></link>
			<title>Biotech is back, with H1 progress smoothing glide path through end of year: Truist</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 11:31:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/deals/pfizer-punts-seagen-adc-further-muddying-value-of-the-43b-buyout]]></guid>
			<link><![CDATA[https://www.biospace.com/deals/pfizer-punts-seagen-adc-further-muddying-value-of-the-43b-buyout]]></link>
			<title>Pfizer punts Seagen ADC, further muddying value of the $43B buyout</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 11:31:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/abbvies-t-cell-engager-delivers-survival-benefit-in-phase-3-multiple-myeloma-study]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/abbvies-t-cell-engager-delivers-survival-benefit-in-phase-3-multiple-myeloma-study]]></link>
			<title>AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 11:31:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/fda/fda-approves-ionis-antisense-drug-as-first-targeted-therapy-for-alexander-disease]]></guid>
			<link><![CDATA[https://www.biospace.com/fda/fda-approves-ionis-antisense-drug-as-first-targeted-therapy-for-alexander-disease]]></link>
			<title>FDA approves Ionis’ antisense drug as first targeted therapy for Alexander disease</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 11:31:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/job-trends/tscan-cuts-75-of-workforce-while-shifting-focus-to-solid-tumor-program]]></guid>
			<link><![CDATA[https://www.biospace.com/job-trends/tscan-cuts-75-of-workforce-while-shifting-focus-to-solid-tumor-program]]></link>
			<title>TScan cuts 75% of workforce while shifting focus to solid tumor program</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 11:31:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/revmeds-newly-approved-rasonque-could-hold-up-in-non-small-cell-lung-cancer]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/revmeds-newly-approved-rasonque-could-hold-up-in-non-small-cell-lung-cancer]]></link>
			<title>RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 11:31:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/business/us-to-grant-up-to-125m-for-personalized-rna-manufacturing-innovation]]></guid>
			<link><![CDATA[https://www.biospace.com/business/us-to-grant-up-to-125m-for-personalized-rna-manufacturing-innovation]]></link>
			<title>US to grant up to $125M for personalized RNA manufacturing innovation</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 11:31:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/drug-development/breaking-borders-building-biotech-scale-in-benelux]]></guid>
			<link><![CDATA[https://www.biospace.com/drug-development/breaking-borders-building-biotech-scale-in-benelux]]></link>
			<title>Breaking borders: Building biotech scale in Benelux</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 11:31:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/job-trends/biopharma-needs-more-data-scientists-whos-getting-hired]]></guid>
			<link><![CDATA[https://www.biospace.com/job-trends/biopharma-needs-more-data-scientists-whos-getting-hired]]></link>
			<title>Biopharma needs more data scientists. Who&#8217;s getting hired?</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 11:31:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/fda/opinion-capricor-replimune-illustrate-why-fda-must-listen-to-rare-disease-specialists]]></guid>
			<link><![CDATA[https://www.biospace.com/fda/opinion-capricor-replimune-illustrate-why-fda-must-listen-to-rare-disease-specialists]]></link>
			<title>Capricor, Replimune illustrate why FDA must listen to rare disease specialists</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 11:31:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/fda/fda-raises-bar-for-foreign-site-inspections-as-china-trials-surge]]></guid>
			<link><![CDATA[https://www.biospace.com/fda/fda-raises-bar-for-foreign-site-inspections-as-china-trials-surge]]></link>
			<title>FDA raises bar for foreign site inspections as China trials surge</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 11:31:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/career-advice/follow-the-money-how-funding-announcements-can-help-identify-jobs-before-theyre-posted]]></guid>
			<link><![CDATA[https://www.biospace.com/career-advice/follow-the-money-how-funding-announcements-can-help-identify-jobs-before-theyre-posted]]></link>
			<title>Follow the money: How funding announcements can help identify jobs before they’re posted</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 11:31:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/fda/uniqure-files-for-fda-uk-approval-of-first-gene-therapy-for-huntingtons-disease]]></guid>
			<link><![CDATA[https://www.biospace.com/fda/uniqure-files-for-fda-uk-approval-of-first-gene-therapy-for-huntingtons-disease]]></link>
			<title>UniQure files for FDA, UK approval of first gene therapy for Huntington’s disease</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 11:31:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/novartis-ionis-pelacarsen-lpa-horizon-study-results-fail/829736/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/novartis-ionis-pelacarsen-lpa-horizon-study-results-fail/829736/]]></link>
			<title>Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 11:31:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/abbvie-multiple-myeloma-etentamig-phase-3-trial-results/829672/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/abbvie-multiple-myeloma-etentamig-phase-3-trial-results/829672/]]></link>
			<title>Trailing rivals, AbbVie scores win with dual-acting myeloma drug</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 11:31:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/mapping-the-dynamic-plant-interactome-new-quantitative-in-vivo-approaches-emerge/]]></guid>
			<link><![CDATA[https://bioengineer.org/mapping-the-dynamic-plant-interactome-new-quantitative-in-vivo-approaches-emerge/]]></link>
			<title>Mapping the Dynamic Plant Interactome: New Quantitative In Vivo Approaches Emerge</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 03:41:46 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/charts-biotech-deals-china-alumis-ultragenyx-stock/829635/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/charts-biotech-deals-china-alumis-ultragenyx-stock/829635/]]></link>
			<title>This week in charts: China deals, stock flatlines and Lilly’s M&amp;A spree</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 11:31:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/ionis-rare-neurology-drug-approved-pfizer-inks-an-adc-deal/829639/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/ionis-rare-neurology-drug-approved-pfizer-inks-an-adc-deal/829639/]]></link>
			<title>Ionis’ rare neurology drug approved; Pfizer inks an ADC deal</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 11:31:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/superluminal-medicines-obesity-ai-drug-discovery-series-b/829552/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/superluminal-medicines-obesity-ai-drug-discovery-series-b/829552/]]></link>
			<title>An AI drug specialist zeroes in on rare forms of obesity</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 11:31:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/gsk-hutchmed-egfr-kras-cancer-drug-deal-china/829542/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/gsk-hutchmed-egfr-kras-cancer-drug-deal-china/829542/]]></link>
			<title>GSK wagers up to $1.3B on a different kind of cancer drug</title>
			<pubDate><![CDATA[Sun, 06 Sep 2026 11:31:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://helixgatebiotechreview.com/]]></guid>
			<link><![CDATA[https://helixgatebiotechreview.com/]]></link>
			<title>Home</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 03:39:54 +0000]]></pubDate>
		</item>
				</channel>
</rss>
